Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization. Recently, Viva's portfolio companies have new updates. Keep reading for more details.

AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211 in Fabry Disease

NEWARK, Calif.--(BUSINESS WIRE)--AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs). On Nov. 1st, 2023, they announced that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease. AL01211 is a novel, oral, non-brain penetrant glucosylceramide synthase (GCS) inhibitor being developed to treat glycosphingolipid storage diseases, including Fabry Disease and Type 1 Gaucher Disease. In Phase 1 trials, AL01211 was generally well tolerated without significant adverse events.

Deka Biosciences Closes USD $20 Million Series B2 Financing Led by MPM BioImpact

GERMANTOWN, Md., Sept. 28, 2023 /PRNewswire/ -- Maryland-based biotech company Deka Biosciences ("Deka"), invested and incubated by Viva BioInnovator (VBI),  announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by Bayer, Lumira Ventures, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm. The proceeds of the financing will support the advancement of Deka's pipeline and drug product manufacturing as they continue clinical trials following the receipt of a notice to proceed letter from the FDA for their investigational new drug (IND) application to evaluate DK210 (EGFR). Additionally, Detlev Biniszkiewicz, Ph.D. of MPM-BioImpact, will join the Deka board.

Triumvira Immunologics Announces First Patient Dosed in Phase II of TACTIC-2 Cell Therapy Trial for the Treatment of HER2+ Gastric and GEJ Cancers

AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 /PRNewswire/ -- Triumvira Immunologics, invested and incubated by Viva BioInnovator (VBI), is a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. Recently they announced that the first patient has been dosed in Phase II of its Phase I/II study TACTIC-2 (NCT04727151) investigating the safety and efficacy of autologous TAC-T cell lead asset, TAC01-HER2, in targeting HER2 in relapsed or refractory gastric and gastroesophageal junction (GEJ) tumors. TAC01-HER2 is a novel cell therapy based on genetically engineered autologous T cells expressing a T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).

VivaVision Ranks on 2023 Top 100 Chinese Healthcare Front-Runners List, and Opens its New Neadquarters in Wenzou

Recently, the 2023 BioShanghai Biopharmaceutical Industry Investment Forum and Future Medical Industry Forum was held at Hongqiao Brg Fund Town, where the "2023 Top 100 Chinese Healthcare Front-Runners List" was officially released. VivaVision, invested and incubated by Viva BioInnovator (VBI), was named on the list. This award fully affirms VivaVison’s strengths. And VivaVision will make full use of its technology and platform advantages to accelerate the translation of drug discovery. Currently, they have already established technical platform from drug discovery to clinical development.

In addition, on October 13th, VivaVision' Wenzhou headquarters and Complex Formulation Research Institute were officially opened! Dr. Wang Shen, Founder and CEO of VivaVision, said the launch of the Wenzhou headquarters marks another new milestone in VivaVision’s development. It will accelerate VivaVison's transition from a company focused solely on ophthalmology drug innovation, to one driven by both "ophthalmic innovative drugs + ophthalmic consumer healthcare" under the "Major Ophthalmology" strategy upgrade. The company will further accelerate the integration of internal and external high-quality resources, talent cultivation, and continue to expand VivaVision's leading edge in ophthalmic innovative drugs through a series of differentiated products and projects based on "independent innovation + win-win cooperation". This will bring VivaVision to a world-leading ophthalmology company rooted in both Wenzhou and China.

About AceLink Therapeutics, Inc.

Founded in 2018, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective medicines to address genetic diseases with high unmet needs. The company’s initial focus is to develop novel therapeutics for Fabry disease. For more information, please visit www.acelinktherapeutics.com.

About Deka Biosciences

Deka Biosciences is a biotech company led by entrepreneur Dr. John Mumm, who is backed by a team of experienced academic, biopharma and CDMO innovators with expertise in drug discovery, product development, characterization, and testing. Deka has developed disease specific Diakines™ designed to maximize patient benefits through improved pharmacokinetics / pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Through developing a better understanding of each patient's immune response to different Diakines™, Deka hopes to maximize the impact of its Diakines™ by building specific targeted therapies for everyone.

About Triumvira Immunologics

Triumvira Immunologics, Inc. ("Triumvira") is a leading clinical-stage solid tumor cell therapy company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company's proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. Triumvira is developing a broad pipeline targeting promising tumor-associated antigens such as HER2, Claudin 18.2, GUCY2C and GPC3. Triumvira is headquartered in Austin, Texas, with research facilities in Hamilton, Ontario, and GMP manufacturing facilities in South San Francisco, California.

About VivaVision Biotech

VivaVision is a clinical stage pharmaceutical company focused on best-in-class and first-in-class therapies for ocular diseases. VivaVision's current pipeline includes VVN001 for treating dry eye syndrome, VVN539 for the treatment for Glaucoma or Ocular Hypertension, and VVN461 for the treatment of non-infectious ocular inflammation of Uveitis. VivaVision is also engaged in discovery and development of novel therapies for the treatment of other anterior and posterior eye diseases.